May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Seyed Alireza Javadinia: Capecitabine-Enhanced Brachytherapy in Locally Advanced Cervical Cancer
Apr 28, 2025, 04:44

Seyed Alireza Javadinia: Capecitabine-Enhanced Brachytherapy in Locally Advanced Cervical Cancer

Seyed Alireza Javadinia, Clinical Oncologist, Vice President for Research and Technology at Sabzevar University of Medical Sciences, shared a post on LinkedIn:

“Thrilled to share that I’ve published a new article in Cancer Investigation, in collaboration with Dr. Indira Giri, Dr. Soudeh Arastouei, and Prof. Malihe Hasanzadeh mofrad!

Our phase II trial, accessible at tandfonline.com, investigates the safety and efficacy of capecitabine as a radiosensitizer during brachytherapy for locally advanced cervical cancer (FIGO stage IB2-IVA). Key findings show that capecitabine is well-tolerated, with manageable side effects like fatigue (55.6%) and nausea (50%), and no significant increase in chronic adverse events. While it numerically prolonged disease-free survival (DFS) and reduced recurrence risk (HR=0.81), the results were not statistically significant (p=0.75), suggesting further research is needed.

Proud of our collaborative effort to advance cervical cancer treatment options, especially in resource-constrained settings!

Please read, share, and share your feedback.”

Capecitabine-Enhanced Brachytherapy in Locally Advanced Cervical Cancer: A Phase II Non-Randomized Trial on Safety and Efficacy

Authors: Fatemeh Homaei Shandiz, Soudeh Arastouei, Sare Hosseini, Seyed Alireza Javadinia et al.

Seyed Alireza Javadinia: Capecitabine-Enhanced Brachytherapy in Locally Advanced Cervical Cancer

More posts featuring Seyed Alireza Javadinia on OncoDaily.